John Dyett

Member, Audit Chair, Compensation Chair

John Dyett has served as a member of our board of directors since January 2017. Mr. Dyett serves as the Co-CEO of Salem Partners, LLC and Salem Partners Wealth Management, LLC. Mr. Dyett helped raise several rounds of venture capital for Adams Respiratory Therapeutics, Inc. which was purchased for $2.3 billion by Reckitt Benckiser in 2008. Mr. Dyett helped launch ZS Pharma, Inc., a specialty pharmaceutical company. ZS Pharma, Inc. completed a successful initial public offering in June 2014 and was subsequently purchased by AstraZeneca for $2.7 billion. Mr. Dyett serves on the investment committee of Salem Partners Wealth Management. Mr. Dyett was also a banker with Gerard Klauer Mattison & Co., Inc. and Needham and Co., Inc. Mr. Dyett previously served on the board of directors of Sierra Total Return Fund. Mr. Dyett also serves on the board of directors of Medley Management and OncoNano Medicine. Mr. Dyett holds a BA in Government and Economics from Harvard College.